Passage BIO, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Remix Therapeutics is merging with Passage Bio in a reverse recapitalization. Remix raised $100M via $30M convertible notes (June 2026) and $70M subscription financing (received by Nov 17, 2026). Exchange agreements converted 85.1M preferred shares and 3M common shares into pre-funded warrants. Post-merger, combined company valued at ~$352.7M with Remix shareholders holding 63%, new investors 29.5%, Passage Bio shareholders 7.5%.
Why this rating
Reverse merger with $100M funding transforms $25.4M Passage Bio into $352.7M combined entity focused on Remix's RNA-modulation pipeline. Addresses going-concern risk; materially expands capital base and valuation relative to both pre-merger companies.
Tradability signal
NO TRADE
No trade: only ~$11k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.61 | +10 min · unknown $3.51 ▼ 2.77% | +30 min · unknown $3.51 ▼ 2.77% | +1 hr · unknown $3.51 ▼ 2.77% | +4 hrs · unknown $3.78 ▲ 4.71% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.